Galectin Therapeutics (GALT) Misses Q3 EPS by 6c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.26), $0.06 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Hyperscale Data launches $300M at-the-market stock offering